Duchenne muscular dystrophy (DMD), the most common inherited neuromuscular disorder, is characterized by progressive muscle wasting and weakness. One third of Duchenne patients suffer a moderate to severe, nonprogressive form of mental retardation. Mutations in the DMD gene are thought to be responsible, with the shorter isoforms of dystrophin implicated in its molecular brain pathogenesis. It is becoming clear that region-specific variations in dystrophin isoforms delegate the composition of the dystrophin-glycoprotein complex in brain, and hence, the function of the specific membrane assembly. Here we summarize the recent advances in the understanding of brain dystrophin, dystrophin-related proteins and dystrophin-associated proteins.
Duchenne muscular dystrophy (DMD), the most common inherited neuromuscular disorder, is characterized by progressive muscle wasting and weakness. One third of Duchennepatients suffer a moderate to severe, nonprogressive form of mental retardation. Mutations in the DMD gene are thought to be responsible, with the shorter isoforms of dystrophin implicated in its molecular brain pathogenesis. It is becoming clear that region-specific variations in dystrophin isoforms delegate the composition of the dystrophin-glycoprotein complex in brain, and hence, the function of the specific membrane assembly. Here we summarize the recent advances in the understanding of brain dystrophin, dystrophin-related proteins and dystrophin-associated proteins.
The elucidation of the gene responsible for the primary defect in Duchenne muscular dystrophy (DMD) led to the discovery of its protein product, a membrane cytoskeletal protein termed
dystrophin. The absence of this protein in patients afflicted
with DMD leads to the characteristic dystrophic phenotype of
progressive muscle weakness and wasting. Although primarily an
inherited disorder of skeletal muscle, the disease also presents
in cardiac muscle and diaphragm, as well as the peripheral and
central nervous system [1, 2].The 427 kd dystrophin (Dp427) isoform, identified as a rod-shaped membrane cytoskeletal protein, can be divided into four
distinct domains (Figure 1) [1, 2, 3]. The amino-terminal region interacts with cortical actin of the membrane cytoskeleton. Twenty-four spectrin-like repeats interrupted by four proline-rich hinge regions comprise the rod-domain, containing a second actin-binding site proximal to the amino-terminus. A cysteine-rich region containing a WW-domain protein-binding motif, together with an EF hand Ca2+-dependent region form the unique carboxy-terminal of Dp427. This domain is believed to bind dystrophin to a series of integral glycoproteins termed the dystrophin-associated proteins (DAPs) [1, 2, 3]. The carboxy-terminus also contains coiled-coil protein-binding motifs (Figure 1), shown to interact with the syntrophin protein family, and the dystrobrevin family of dystrophin-related/dystrophin-associated proteins. This group of proteins recruits signalling elements such as the neuronal nitric oxide synthase (nNOS) and Grb2, and is also implicated in the clustering of ion channels such as voltage-gated Na+-channels [3, 4].
Figure 1
Dystrophin and the dystrophin-related proteins specific to brain. Schematic representation of dystrophin and the dystrophin-related proteins, and the similarities shared by each protein. Shown are the four distinct regions of dystrophin: the amino-terminus, the rod-domain interrupted by the four proline-rich hinge regions, the cysteine-rich domain, and the carboxy-terminus. Abbreviations used: Hinge: hinge regions, Cysteine: cysteine-rich domain, WW: PPxY-binding WW motif, EF: Ca2+-dependent twin EF-hand motifs, ZZ: Zn2+-dependent zinc fingers, α-H:
α-helical domain, L-H helical leucine heptads which makeup
the coiled-coil domain, DUR: dystrobrevin-unique region, Y:
region of tyrosine phosphorylation.
A chromosome 6-encoded autosomal homologue of dystrophin named utrophin (Figure 1) has also been shown to interact with the DAPs [3]. Utrophin is localized to the neuromuscular junction [2], where interactions of utrophin with the DAPs, rapsyn and agrin lead to clustering of nicotinic acetylcholine receptors at the postsynaptic membrane in the junctional folds. The tertiary structure of utrophin is similar to that of dystrophin, however one less spectrin-like repeat results in a 395 kd-protein transcript. Utrophin contains a unique amino-terminus, with an absence of a similar actin-binding site of the dystrophin rod domain [2]. Binding to β-dystroglycan is also mediated by a WW domain, with the interaction stabilized by an adjacent EF-hand region [5]. An interaction of utrophin with the cytoplasmic components associated with dystrophin has also been demonstrated, mediated by coiled-coil motifs [3].
BRAIN DYSTROPHIN-GLYCOPROTEIN COMPLEX
Brain abnormalities, presented in the form of a moderate to
severe, nonprogressive mental retardation, are manifest in one
third of the patients affected by DMD [6]. The abnormality is evident as developmental cognitive and behavioural abnormalities, including deficits in overall and verbal IQ, as well as attention deficits and impaired short-term memory processing [6, 7].
Analysis of the dystrophin gene revealed the presence of eight
different promoters scattered throughout the gene, driving
tissue-specific distribution of full-length dystrophins and
several shorter isoforms. Full-length Dp427 isoforms were
discovered in brain, as well as three shorter C-terminal transcripts. Downstream promoters drive the expression of a 140 kd isoform termed Dp140, and the 71 kd major brain isoform Dp71
(see Figure 1 and Table 1) [2]. Common to all the brain dystrophin isoforms is the inclusion of the WW-motif and EF-hand region, as well as the coiled-coil regions. Therefore, a link is maintained to the integral membrane protein β-dystroglycan, as well as to the members of the
cytoplasmic component of the dystrophin-glycoprotein complex
(DGC). The shorter isoforms lack the actin-binding domains of the
muscle dystrophin isoform, although the N-terminus of Dp71
contains a unique N-terminal actin-binding domain.
The brain DGC consists of four main components: the dystroglycan
subcomplex, a dystrophin or utrophin isoform, a
dystrobrevin isoform, and a syntrophin subcomplex.
Table 1
Location of the brain isoforms of dystrophin throughout the brain.
Dystrophin isoform
Cellular location
Dp427-M
Glia and vascular endothelial cells
Dp427-C
Cortical and hippocampal (CA 1-3 region) pyramidal neurons
Dp427-P
Fetal cerebral cortex and mature cerebellar purkinje cells
Dp140
Astroglial processes throughout the neuropil during development
Leptomeningeal surfaces and along penetrating blood vessels
Ensheathing the olfactory nerve
Neurohypophysis
Dp116
Late human fetal brain
Caudate/putamen region
Dp71
Early embryonic stem cells
Mesenchymal-epithelial interactions
Embryonic midbrain and hindbrain
Perinatal brain at stages of terminal neural differentiation
Early embryonic forebrain continuing until adult life
Cerebral cortex
Granule neurons of dentate gyrus of hippocampus
Neocortial regions (neurogenesis and synaptic plasticity)
Olfactory bulb
Pituitary gland
Retina
DYSTROGLYCAN SUBCOMPLEX
The backbone of the brain DGC is the transmembrane link generated by the presence of α- and β-dystroglycan. These proteins act to form an integral sarcolemmal linkage, localizing
dystrophin to the subsarcolemmal region. A proline-rich region at
the extreme carboxy-terminus of β-dystroglycan
mediates this interaction with dystrophin and its isoforms. As
with the muscle complex, binding is mediated by the WW domain of
dystrophin, stabilized by the adjacent EF-hand region
[5]. However, the lack of sarcoglycans in the brain, in
particular δ-sarcoglycan, which is found in close
proximity to α- and β-dystroglycan in muscle, has
led to the speculation that a more tenuous binding exists between
the dystroglycans and dystrophin [8]. Chemical crosslinking
of brain β-dystroglycan results in the stabilization of a
high-molecular mass complex (Figure 2a) [2]. On
the other hand, perfluoro-octanoic acidpolyacrylamide gel
electrophoresis (PFO-PAGE) analysis, performed as described in
reference [9], indicates that the monomeric form of
α-dystroglycan prevails in brain over the
oligomerized forms seen in skeletal and cardiac muscle
(Figure 2b). The recent analysis of the dystrophic mdx
mouse model demonstrated abnormal oligomerization of the
neuronal Dp71 isoform suggesting its involvement in the
pathophysiological mechanisms underlying abnormal brain functions
[10].
Figure 2
Analysis of the brain dystroglycan complex. Panel (a) shows
the chemical cross-linking analysis of β-dystroglycan
(β-DG) of apparent 43 kd in normal mouse brain using the
hydrophilic probe bis-sulfosuccinimidyl-suberate (BS3) and sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Detection of this sarcolemmal protein was achieved by
immuno-decoration with monoclonal antibody NCL-b-DG [10]. Lanes 1–6 represent 0, 25, 50, 100, 200, and 300 μg BS3/mg protein, respectively. Increasing concentrations of crosslinker (XL) clearly stabilized a high-molecular-mass complex demonstrating the oligomeric status of brain β-dystroglycan. In panel (b), is shown the perfluoro-octanoic acid polyacrylamide gel electrophoresis (PFO-PAGE) [9] analysis of α-dystroglycan (α-DG). Lanes 1 to 3 represent mouse skeletal muscle, cardiac muscle, and brain microsomal membranes, respectively. The highly glycosylated, extracellular protein α-dystroglycan was immuno-decorated employing monoclonal antibody VIA12
[10] . Compared to skeletal and cardiac muscle, the dystroglycan sub-complex was not preserved in brain by this method, indicating a more tentative dystroglycan binding in the
central nervous system. The position of monomers and oligomers is
marked by closed and open arrow heads, respectively. The relative
position of molecular mass markers (in kd) is indicated on the
left of blots.
Structural analysis of β-dystroglycan has indicated numerous
possibilities for the interaction of β-dystroglycan with
signalling and second-messenger proteins. Two WW-binding domains
have been identified from the sequence of β-dystroglycan,
although only one ligand for these sites is known. Several
SH3-binding domains have also been identified, although only the
intracellular adapter protein Grb2 has been shown to interact with
β-dystroglycan. The identification of the Grb2-interacting
protein focal adhesion kinase as a component of the DGC, a known
phosphorylator of the DGC, still remains elusive [5, 8].The extracellular matrix component α-dystroglycan, a 156
kd heavily glycosylated protein interacts with the
amino-terminal region of β-dystroglycan. In muscle,
α-dystroglycan has been demonstrated to act as a receptor
for several different ligands. Bindings to proteins
such as the α2-chain of laminin-1, 2 and 8 have been
demonstrated, as well as perlecan and agrin [8].
Implications have been made for the interaction of
α-dystroglycan with pathogenic viruses such as leprosy and
lassa fever viruses [8]. Recently, three different
glycosylation states of α-dystroglycan have been
identified in muscle, leading to the postulation that the extent
of glycosylation of α-dystroglycan plays a key role in the
formation of complexes with extracellular proteins [11].
With the binding sites for laminin and perlecan in close
proximity, differential glycosylation of α-dystroglycan
may lead to exposure of the relevant ligand-binding site leading
to selective recruitment of extracellular binding proteins.Quantitative studies on laminin, perlecan, and agrin in brain
tissue indicate that the levels of these proteins expressed in
brain are less significant than that of α-dystroglycan.
Agrin has been implicated to interact with Dp71 in astrocytes,
while laminin has been localized to the glial-vascular interphase
of the capillary basement membrane. Recently, a presynaptic
neuronal protein involved in cell aggregation was identified as a
neuron-specific α-dystroglycan-binding protein. The
polymorphic cell-surface proteins, α- and
β-neurexins, have been demonstrated as binding partners for
neuronally expressed dystrophin through an interaction with
α-dystroglycan. The interaction links the neuronal
postsynaptic membrane through α-dystroglycan with the
presynaptic membrane through the neurexins, mediating cell
aggregation [12]. As diagrammatically shown in
Figure 3, it is becoming increasingly clear that different
DGCs exist in the central nervous system [13].
Figure 3
Variations in the brain dystrophin-glycoprotein complex. Schematic representation of the established members of established
dystrophin-glycoprotein complexes (DGC), and their associations
with other peripheral proteins. Shown are a neuronal complex, a
glial complex, and a general vascular complex. A dystrophin or
utrophin isoform links to the α/β-dystroglycan (DG)
backbone and a dystrobrevin (DYB) isoform. An association with the
extracellular matrix (ECM) by α-dystroglycan is maintained
through agrin (AGR) or laminin (LAM). In neurons, α-dystroglycan is associated with neurexin (NXN), linking the presynaptic membrane (PRE) to the postsynaptic density (PSD).
Other α-dystroglycan ligands are represented by agrin
(AGR) and laminin (LAM). Syntrophin isoforms (α1,
β2, γ1, or γ2) recruit neuronal nitric oxide
synthase (nNOS) to the complex, as well as other nonestablished
voltage-gated ion-channels (Ion Ch) and/or kinases (KIN). For
abbreviations of binding domains see Figure 1.
BRAIN DYSTROPHINS
Localization studies have determined a neuronal distribution of Dp427, being associated with the postsynaptic density. Three
full-length dystrophin isoforms have been established, resulting
from different promoters, differing only in their amino-terminal
makeup and their cellular location. The shorter Dp140 isoform of
dystrophin is comprised of the distal part of the rod domain, and
an identical carboxy-terminus to that of full-length dystrophin.
Expression profiles of Dp140 show an ubiquitous distribution
throughout the brain, being localized to penetrating cerebral
microvasculature and expressed predominantly during fetal
development [6].The major dystrophin protein product in brain, Dp71, is expressed in astrocytes and glial cells [14, 15]. Lacking the actin-binding domain of full-length dystrophin and the spectrin-like repeats, Dp71 retains the carboxy-terminal region, the cysteine-rich domain, and part of the hinge region proximal to the cysteine-rich domain. The transmembrane link is maintained by an interaction with β-dystroglycan, which in turn interacts with α-dystroglycan. Recently, two alternative splicing sites were determined. Although one of the sites has no effect on the protein, the other site, which omits exon 78, results in the addition of a hydrophobic carboxy-terminal region to the isoform. The alternative splicing of Dp71 regulates its subcellular localization, with the alternatively spliced hydrophilic isoform localized to the nucleus [16]. Less is known about the localization of utrophin Up395, and its alternatively spliced isoforms Up62, Up71, and Up113. All three isoforms contain the carboxy-terminal and cysteine-rich domains, similar to their dystrophin counterparts (Figure 1) [2]. The utrophin has a ubiquitous distribution throughout the brain, and is believed to be associated with astroglial processes surrounding the microvasculature. Up113 (G-utrophin) is found in the postsynaptic density of distinct brain regions diverse from those of dystrophin. Up62 (N-utrophin) is found in glioma cells.
DYSTROBREVINS
The interaction of dystrobrevin with dystrophin occurs via one of the two helical leucine heptads of the coiled-coil region
[4]. The specificity of the dystrobrevin, α- or β-dystrobrevin, is dependent on the isoform of dystrophin present in the tissue region. Co-immunoprecipitation studies have identified α-dystrobrevins, in particular α-dystrobrevin-1, as the binding partner to Dp71 in Bergmann glial cells [17]. An association with utrophin is believed to occur in perivascular astrocytes. The major 62 kd β-dystrobrevin isoform has been found in neurons and in the hippocampal formation, most likely associated with the full-length dystrophin isoform [18]. Co-immunoprecipitation has revealed Dp140 as a binding partner to β-dystrobrevin, although this protein is not found in the microvasculature. An association of β-dystrobrevin with utrophin has also been demonstrated. In the cerebellum, β-dystrobrevin has been shown to be nuclear-located, probably associated with the
previously undetected hydrophilic Dp71.
SYNTROPHINS
The syntrophin family of proteins are a family of closely related
59 kd proteins containing PDZ domains, allowing the recruitment
of signalling proteins and ion channels to the DGC. In the brain,
co-precipitation of α1-syntrophin has been shown with
neuronal dystrophin. β2-syntrophin has a more ubiquitous
expression throughout the brain, mimicking the expression of
utrophin in the cerebral microvasculature [19]. Recently,
two brain-specific syntrophins, γ1- and
γ2-syntrophin, have been identified. γ1-syntrophin
has been shown to be restricted to neurons, presumably
associating with dystrophin, while γ2-syntrophin has been
demonstrated to have a more ubiquitous expression in brain, and
to a lesser extent in nonbrain tissue. The function of these and
other syntrophins still remains unclear, although one can assume
that the role is one of receptor or signalling-protein recruitment.
CONCLUSIONS
The role of dystrophin, dystrophin-like, and dystrophin-associated proteins in the molecular pathogenesis of mental
retardation in DMD is complex, and to a large extent still
elusive. Although mutations in the DMD gene are the primary defect believed to cause this phenomenon, with mutations in Dp140 [20] and Dp71 [6] implicated, it is more probable that the secondary effects of these mutations result in the specificity of the condition. The multifunctional
aspect of the DGC adds to its complexity in brain. The extracellular component mediates cellular signalling through interactions of specific proteins such as laminin, merosin, perlecan, agrin, and biglycan [8]. These interactions are believed to play a role in terminal consolidation, integrity, and maintenance. Other interacting proteins, such as the newly discovered DAP neurexin [12], function to maintain cell
associations, while certain viruses, such as those causing lassa
fever and leprosy, utilise the complex to mediate entry to the
host [5, 8]. The cytoplasmic element of the DAPs act as adapter proteins for signalling proteins. Syntrophins and dystrobrevins recruit signalling elements such as the voltage-gated sodium channels, as well as nNOS, SAP kinase, and ErbB2 [4, 17, 19]. Syntrophins also interact with calmodulin
suggesting a potential role in Ca2+-homeostasis. The
cytoplasmic element of β-dystroglycan is required for the interaction of rapsyn with the nicotinic acetylcholine receptor. Recruitment of the adapter protein Grb2 also occurs [5, 8]. Evidence is mounting for the participation of the DGC in long-term memory formation. β-dystrobrevin has been shown to translocate to the nucleus, mediated by zinc finger ZZ domains, common amongst proteins known to migrate to the membrane from the nucleus. Recent studies have revealed a novel hydrophilic Dp71 isoform, formed through alternate splicing of the extreme carboxy-terminus [16], and may be the dystrophin
isoform involved. Recruitment of signalling proteins, such as
nNOS, to β-dystrobrevin has also been demonstrated. This
selective recruitment to the DGC holds implications for the Ca2+-dependent cell death processes: a loss of dystrophin resulting in the cell being more susceptible to metabolic or physiological insult. This process would correlate with the finding that the neurons of the brains of DMD sufferers show an increase in neuronal cell death.
Authors: Su Xu; Da Shi; Stephen J P Pratt; Wenjun Zhu; Andrew Marshall; Richard M Lovering Journal: Neuromuscul Disord Date: 2015-07-10 Impact factor: 4.296
Authors: Ilja Boor; Machiel Nagtegaal; Wouter Kamphorst; Paul van der Valk; Jan C Pronk; Jack van Horssen; Argirios Dinopoulos; Kevin E Bove; Ignacio Pascual-Castroviejo; Francesco Muntoni; Raúl Estévez; Gert C Scheper; Marjo S van der Knaap Journal: Acta Neuropathol Date: 2007-07-13 Impact factor: 17.088
Authors: Sandra Murphy; Margit Zweyer; Michael Henry; Paula Meleady; Rustam R Mundegar; Dieter Swandulla; Kay Ohlendieck Journal: Clin Proteomics Date: 2015-11-23 Impact factor: 3.988